Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug MK-1200 tested in advanced cancer patients

NCT ID NCT06242691

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

13 people

The number who actually took part.

Started

Feb 2024

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed advanced (unresectable and/or metastatic) solid tumor: gastric cancer (including gastroesophageal junction cancer), esophageal cancer, biliary tract cancer, or pancreatic ductal adenocarcinoma * Participants who experienced Adverse Events (AEs) due to previous anticancer therapies must have recovered to \< Grade 1 or baseline * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy * Hepatitis B surface antigen (HBsAg) positive participants are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load * Participants with a history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable * Received and progressed on or after 1 or 2 prior lines of therapy Exclusion Criteria: * Active severe digestive disease * History of acute myocardial infarction; unstable angina; stroke or transient ischemic attack within 6 months prior to the first dose of study intervention * Diabetes or hypertension that cannot be controlled by medication * HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Received prior systemic anticancer therapy including investigational agents within 4 weeks before study intervention * Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids * Known additional malignancy that is progressing or has required active treatment within the past 2 years * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Active infection requiring systemic therapy * Have not adequately recovered from major surgery or have ongoing surgical complications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

biliary tract cancer esophageal cancer gastric cancer gastroesophageal cancer gastroesophageal junction adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumors

Contacts and locations

Locations

  • Beijing Cancer hospital-Digestive Oncology ( Site 0401)

    Beijing, Beijing Municipality, 100142, China

  • Bradfordhill-Clinical Area ( Site 0301)

    Santiago, Region M. de Santiago, 8420383, Chile

  • First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0415)

    Huai'an, Jiangsu, 223300, China

  • Fujian Cancer Hospital-oncology department ( Site 0409)

    Fuzhou, Fujian, 350000, China

  • Hadassah Medical Center ( Site 0604)

    Jerusalem, 9112001, Israel

  • Rabin Medical Center-Oncology ( Site 0603)

    Petah Tikva, 4941492, Israel

  • Rambam Health Care Campus-Oncology Division ( Site 0602)

    Haifa, 3109601, Israel

  • START Midwest ( Site 0014)

    Grand Rapids, Michigan, 49546, United States

  • START Mountain Region ( Site 0015)

    West Valley City, Utah, 84119, United States

  • Samsung Medical Center-Division of Hematology/Oncology ( Site 1003)

    Seoul, 06351, South Korea

  • Sheba Medical Center ( Site 0605)

    Ramat Gan, 5265601, Israel

  • Sourasky Medical Center ( Site 0601)

    Tel Aviv, 6423906, Israel

  • South Texas Accelerated Research Therapeutics (START) ( Site 0005)

    San Antonio, Texas, 78229, United States

  • The Alfred Hospital ( Site 0103)

    Melbourne, Victoria, 3004, Australia

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0004)

    Louisville, Kentucky, 40202, United States

  • University of Virginia Health System-Hematology-Oncology ( Site 0009)

    Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.